Saturday, August 26, 2017

The new paradigm in the treatment of chronic hepatitis C disease: Faster, Higher and Stronger

Citius Altius Fortius: The new paradigm in the treatment of chronic hepatitis C disease

Aug 26, 2017

Download Full Text Article
Provided By Henry E. Chang‏ via Twitter

Abraham GM, et al. – This study focuses on the treatment of chronic hepatitis C disease. Findings reveal that most of the direct–acting antiviral agents (DAAs) for chronic hepatitis C infection had a high barrier to resistance and are extremely well–tolerated by patients. DAAs, in addition, demonstrate 90% or higher efficacy rates.
  • The treatment paradigm for chronic hepatitis C infection has dramatically changed with the advent of the direct–acting antiviral agents (DAAs), especially the duration, tolerability and response to therapy.
  • The DAAs are classified in to several classes and are variously indicated in the treatment of one or more genotypes of infection.
  • All these agents are orally administered, and they, in majority, are eliminated renally (with exceptions), and don'’t require adjustment in mild to moderate renal insufficiency.
Abstract
With the advent of the direct-acting antiviral agents (DAAs) for chronic hepatitis C infection, the treatment paradigm has dramatically changed, especially the duration, tolerability and response to therapy. The DAAs fall into several classes and are variously indicated in the treatment of one or more genotypes of infection. All these agents are orally administered, and they are largely renally eliminated (with exceptions), don’t require adjustment in mild to moderate renal insufficiency. Most of these agents demonstrate a high barrier to resistance and are extremely well-tolerated by patients. Overall efficacy rates are 90% or higher.
Download Article

Of Interest
Systematic review: cost-effectiveness of DAAs for treatment of HCV genotypes 2-6

New At Hepatitis C Online:
Vosevi and Mavyret
Information on Gilead's newly FDA approved Vosevi and AbbVie's Mavyret  is now available.

Full Text Articles
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading full text articles about the treatment and management of hepatitis C.

No comments:

Post a Comment